Archiv
Archiv anzeigen:
bis


Improved Regorafenib Dosing for Refractory Metastatic Colorectal Cancer

David H. Ilson, MD, PhD reviewing Bekaii-Saab TS et al. Lancet Oncol 2019 Aug

The rate of completing two cycles of therapy and starting a third was significantly higher with a dose-escalation strategy than with standard dosing.


JAK2 and Calreticulin Mutations in the General Population

Brady L. Stein, MD, MHS reviewing Cordua S et al. Blood 2019 Aug 1

JAK2 and CALR mutations are prevalent in the general population, especially in smokers, and those with JAK2 mutations have excess risk for venous thromboembolism.


Bevacizumab for Advanced EGFR-Mutant Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Stinchcombe TE et al. JAMA Oncol 2019 Aug 8

In contrast to prior studies, adding bevacizumab to erlotinib provides no progression-free survival benefit for treatment-naive patients.


Artificial Intelligence to Assess Hormonal Status of Breast Cancer Patients

William J. Gradishar, MD reviewing Shamai G et al. JAMA Netw Open 2019 Jul 26

A machine learning technique was noninferior to traditional immunohistochemistry in predicting molecular biomarker expression.


Do PPIs Prevent GI Bleeding in Patients on Aspirin and Direct Oral Anticoagulants?

John R. Saltzman, MD reviewing Moayyedi P et al. Gastroenterology 2019 Aug

Proton-pump inhibitors did not reduce upper gastrointestinal bleeding in patients with stable cardiovascular disease.


What Is the Optimal Neoadjuvant Taxane Therapy for Breast Cancer?

William J. Gradishar, MD reviewing Untch M et al. J Clin Oncol 2019 May 13, Ross M et al. J Clin Oncol 2019 Jul 15

Outcomes were superior with nab-paclitaxel versus sb-paclitaxel.


Long-Term Recurrence Rates After Unprovoked Venous Thromboembolism

Allan S. Brett, MD reviewing Khan F et al. BMJ 2019 Jul 24

When anticoagulation is stopped after initial treatment, cumulative incidence of recurrent VTE is 10%, 16%, 25%, and 36% at 1, 2, 5, and 10 years, respectively.


Thrombosis Risk with High Platelet Counts and Hematocrit Values

Brady L. Stein, MD, MHS reviewing Warny M et al. J Thromb Haemost 2019 Jul 15

Incidental increases in platelet counts and hematocrit values were associated with ischemic stroke and myocardial infarction, respectively.


Cancer Therapy Can Affect Course of Inflammatory Bowel Disease

Sunanda V. Kane, MD, MSPH reviewing Axelrad JE et al. Clin Gastroenterol Hepatol 2019 Jul 11

Hormonal therapies are associated with higher risk for disease activity.


Recombinant Zoster Vaccine Effective After Autologous Stem Cell Transplant

Daniel Kaul, MD reviewing Bastidas A et al. JAMA 2019 Jul 9

Incidence of herpes zoster infection was significantly reduced with adjuvanted recombinant zoster vaccine versus placebo in a high-risk immunosuppressed group.


Archiv
Seite von 83
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Do CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer?

William J. Gradishar, MD reviewing Turner NC et al. N Engl J Med 2018 Oct 20

Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.


Immunotherapy for Breast Cancer Has Arrived

William J. Gradishar, MD reviewing Schmid P et al. N Engl J Med 2018 Oct 20

Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.


Brigatinib for ALK-Positive, Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Camidge DR et al. N Engl J Med 2018 Sep 25

Progression-free survival was prolonged with front-line brigatinib versus crizotinib.


Front-Line Therapy for Extensive-Stage, Small Cell Lung Cancer: A New Standard

Anne S. Tsao, MD reviewing Horn L et al. N Engl J Med 2018 Sep 25

Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.


A New Standard of Care for Squamous Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Paz-Ares L et al. N Engl J Med 2018 Sep 25

Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.


Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2018 Sep 25

Two-year overall survival was significantly improved with durvalumab versus placebo.


Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer

William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5

Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.


Olaparib plus Abiraterone for Advanced Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Clarke N et al. Lancet Oncol 2018 Jul

Progression-free survival was significantly longer with olaparib than with placebo.


Combination Immunotherapy for Metastatic Melanoma with Brain Metastases

Sunandana Chandra, MD, MS reviewing Tawbi HA et al. N Engl J Med 2018 Aug 23, Turajlic S and Larkin J. N Engl J Med 2018 Aug 23

Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.